Literature DB >> 14534311

Bcl-XL mutations suppress cellular sensitivity to antimycin A.

Michael K Manion1, Jason W O'Neill, Chris D Giedt, Kristine M Kim, Kam Y Z Zhang, David M Hockenbery.   

Abstract

Cells expressing high levels of the BCL-X(L) anti-apoptotic protein are preferentially killed by the mitochondrial inhibitor antimycin A (AA). Computational modeling predicts a binding site for AA in the extended hydrophobic groove on BCL-X(L), previously identified as an interface for dimerization to BAX and related proapoptotic proteins. Here, we identify BCL-X(L) hydrophobic groove mutants with normal cellular anti-apoptotic function but suppressed sensitivity to AA. The LD(50) of AA for cells expressing BCL-X(L) mutants directly correlates with the measured in vitro dissociation constants for AA binding. These results indicate that BCL-X(L) is a principal target mediating AA cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14534311     DOI: 10.1074/jbc.M306021200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Dynamics of the BH3-Only Protein Binding Interface of Bcl-xL.

Authors:  Xiaorong Liu; Alex Beugelsdijk; Jianhan Chen
Journal:  Biophys J       Date:  2015-09-01       Impact factor: 4.033

2.  A rapid coarse residue-based computational method for x-ray solution scattering characterization of protein folds and multiple conformational states of large protein complexes.

Authors:  Sichun Yang; Sanghyun Park; Lee Makowski; Benoît Roux
Journal:  Biophys J       Date:  2009-06-03       Impact factor: 4.033

3.  Molecular basis of the interaction between the antiapoptotic Bcl-2 family proteins and the proapoptotic protein ASPP2.

Authors:  Chen Katz; Hadar Benyamini; Shahar Rotem; Mario Lebendiker; Tsafi Danieli; Anat Iosub; Hadar Refaely; Monica Dines; Vered Bronner; Tsafrir Bravman; Deborah E Shalev; Stefan Rüdiger; Assaf Friedler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-21       Impact factor: 11.205

4.  Role of protein flexibility in the design of Bcl-X(L) targeting agents: insight from molecular dynamics.

Authors:  William Novak; Hongming Wang; Goran Krilov
Journal:  J Comput Aided Mol Des       Date:  2008-09-09       Impact factor: 3.686

Review 5.  Oncogenic protein interfaces: small molecules, big challenges.

Authors:  Tracy L Nero; Craig J Morton; Jessica K Holien; Jerome Wielens; Michael W Parker
Journal:  Nat Rev Cancer       Date:  2014-03-13       Impact factor: 60.716

6.  Crystal Structures of Anti-apoptotic BFL-1 and Its Complex with a Covalent Stapled Peptide Inhibitor.

Authors:  Edward P Harvey; Hyuk-Soo Seo; Rachel M Guerra; Gregory H Bird; Sirano Dhe-Paganon; Loren D Walensky
Journal:  Structure       Date:  2017-12-21       Impact factor: 5.006

7.  Bcl-x(L) prevents apoptosis of late-stage erythroblasts but does not mediate the antiapoptotic effect of erythropoietin.

Authors:  Melissa M Rhodes; Prapaporn Kopsombut; Maurice C Bondurant; James O Price; Mark J Koury
Journal:  Blood       Date:  2005-05-17       Impact factor: 22.113

8.  Ceramide channels: destabilization by Bcl-xL and role in apoptosis.

Authors:  Kai-Ti Chang; Andriy Anishkin; Gauri A Patwardhan; Levi J Beverly; Leah J Siskind; Marco Colombini
Journal:  Biochim Biophys Acta       Date:  2015-07-26

9.  High-resolution structural characterization of a helical alpha/beta-peptide foldamer bound to the anti-apoptotic protein Bcl-xL.

Authors:  Erinna F Lee; Jack D Sadowsky; Brian J Smith; Peter E Czabotar; Kimberly J Peterson-Kaufman; Peter M Colman; Samuel H Gellman; W Douglas Fairlie
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

Review 10.  Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents.

Authors:  Benjamin D Zeitlin; Isaac J Zeitlin; Jacques E Nör
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.